Preterm Birth and 17OHP — Why the FDA Should Not Withdraw Approval
نویسندگان
چکیده
منابع مشابه
Why focus on preterm birth and stillbirth?
While under-5 mortality rates are improving in many countries worldwide, neonatal mortality rates (deaths in the fi rst 28 days of life) have shown much less progress [1]. Neonatal deaths now account for more than 42% of under fi ve deaths (Figure 1), up from 37% in the year 2000 when the Millennium Development Goals (MDGs) were set [2, 3]. MDG 4 targets a two-thirds reduction of under-fi ve de...
متن کاملThe Fundamental Reasons Why Laptop Computers should not be Used on Your Lap
As a tendency to use new technologies, gadgets such as laptop computers are becoming more popular among students, teachers, businessmen and office workers. Today laptops are a great tool for education and learning, work and personal multimedia. Millions of men, especially those in the reproductive age, are frequently using their laptop computers on the lap (thigh). Over the past several years, ...
متن کاملOn Why the United States Should Not Attack Iran: A Conservative, Evangelical Christian Response
In the midst of American intervention in Afghanistan and Iraq, and in the aftermath of the presidential election in Iran, support for American involvement in Iran has increased in some circles. In this piece, our desire is to give a conservative, evangelical Christian response to why America should not support any military action against Iran. A position advocated by many of us is “Just War.” I...
متن کاملFDA drug approval summaries: fulvestrant.
Patients with hormone-sensitive breast cancer who have responded to tamoxifen may receive additional benefit from a second endocrine agent following progression or relapse after tamoxifen therapy. Fulvestrant (Faslodex((R)), ICI 182780, AstraZeneca Pharmaceuticals; Wilmington, Delaware) is a selective antagonist of estrogen designed to have no estrogenic effects. Lack of aqueous solubility led ...
متن کاملFDA drug approval summaries: oxaliplatin.
The purpose of this report is to summarize information on oxaliplatin, a drug recently approved by the U.S. Food and Drug Administration. Information provided includes regulatory history, study design, efficacy and safety results, and pertinent literature references. A single, multicenter, randomized trial, enrolling 463 patients with metastatic colorectal carcinoma whose disease had recurred o...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: New England Journal of Medicine
سال: 2020
ISSN: 0028-4793,1533-4406
DOI: 10.1056/nejmp2031727